Drug details:
Molecular formula: C₂₂H₁₅FN₄O₄

Standard name: (E)-3-(4-fluorophenyl)-N-[4-(1-hydroxy-6-nitrobenzimidazol-2-yl)phenyl]prop-2-enamide

Curated SMILES: O=C(/C=C/C1=CC=C(F)C=C1)NC1=CC=C(C2=NC3=CC=C([N+](=O)[O-])C=C3N2O)C=C1

Evidence for compound's anti-virulence activity:

Pseudomonas
Related VF: TTSS (Type III secretion system)
Target: ExsA
Drug effect: Inhibits DNA binding by interacting specifically with the DNA-binding domain of ExsA and its homologs AscA, LscA, LcrF, ExsAvp (from Vibrio parahaemolyticus).
Max phase: Preclinical (in vitro)
Publication:
Marsden AE, et al., 2016. Inhibition of Pseudomonas aeruginosa ExsA DNA-Binding Activity by N-Hydroxybenzimidazoles. Antimicrob Agents Chemother 60(2):766-76.

Yersinia
Related VF: TTSS (Type III secretion system)
Target: VirF/LcrF
Drug effect: Targets the conserved DNA-binding domain of LcrF.
Max phase: Preclinical (in vitro)
Publication:
Kim OK, et al., 2009. N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents. J Med Chem 52(18):5626-34.

Yersinia
Related VF: TTSS (Type III secretion system)
Target: VirF/LcrF
Drug effect: Targets the conserved DNA-binding domain of LcrF.
Max phase: Preclinical (in vivo)
Publication:
Garrity-Ryan LK, et al., 2010. Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model. Infect Immun 78(11):4683-90.